David Michael Andrews

statsborgerskab: Storbritannien

uddannelsessted: Liverpools Universitet

beskæftigelse: forsker, biokemiker, medicinsk forsker, kemiker, organisk kemiker

Serier

There is nothing here

Create a new serie

Artikler

There is nothing here

Create a new work

Artikler 29

Date

Titel

Forfattere

2017-08-02

Progress towards a public chemogenomic set for protein kinases and a call for contributions

David Drewry, David Michael Andrews, Jonathan M Elkins, Susanne Müller, Stefan Laufer, Nathanael Gray
2017-08-10

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins

David Michael Andrews, Paul E Brennan, Stefan Knapp, Paul V Fish, Cynthia Tallant
2017-01-09

Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies

Pavel Savitsky, David Michael Andrews, Susanne Müller, Paul E Brennan, Tim C P Somervaille, Cynthia Tallant
2016-02-23

The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot

David Michael Andrews, Laura M Broad, Timothy Gallagher, Stephen L Garland, Richard Kidd, Joseph B. Sweeney
2015-10-07

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

David Michael Andrews
2015-06-04

Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα)

David Michael Andrews
2015-06-29

Compound Passport Service: supporting corporate collection owners in open innovation

David Michael Andrews
2014-01-28

Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface

David Michael Andrews
2013-12-24

Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation

David Michael Andrews
2012-05-21

Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase

David Michael Andrews, Andrew Leach
2011-07-02

Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

David Michael Andrews
2008-06-12

Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode

David Michael Andrews
2008-09-10

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors

David Michael Andrews
2008-10-25

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing

David Michael Andrews, Kin Tam
2008-10-22

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

David Michael Andrews
2008-03-16

Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors

David Michael Andrews
2008-03-22

Design and campaign synthesis of pyridine-based histone deacetylase inhibitors

David Michael Andrews
2007-02-02

Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate

David Michael Andrews, Helen P Price
2005-01-26

Applications of the amino-Cope rearrangement: synthesis of tetrahydropyran, delta-lactone and piperidine targets

Munira Essat, Vickie McKee, David Michael Andrews, Steven M Allin
2003-11-01

Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease

David Michael Andrews
2003-04-01

The design of potent, non-peptidic inhibitors of hepatitis C protease

David Michael Andrews
2003-05-01

Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

David Michael Andrews
2003-02-01

Short and versatile route to a key intermediate for lactacystin synthesis

Philip C Bulman Page, Steven M Allin, David Michael Andrews
2003-11-01

Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease

David Michael Andrews
2002-12-01

Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents

David Michael Andrews
2002-12-01

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease

David Michael Andrews
2002-12-01

Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

David Michael Andrews
1993-08-01

Solid-phase synthesis of O-mannosylated peptides: two strategies compared

David Michael Andrews
1991-11-01

Solid-phase synthesis of a range of O-phosphorylated peptides by post-assembly phosphitylation and oxidation

David Michael Andrews

Human - wd:Q38544031

Welcome to Inventaire

dit venne- og fællesskabs bibliotek

vil du vide mere